To evaluate the safety and efficacy of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS+ HIPEC) in patients with peritoneal carcinomatosis from colorectal carcinoma (CRC PC). The clinical and follow-up data of 90 consecutive CRC PC patients underwent CRS+ HIPEC in Beijing Shijitan Hospital from January 2015 to June 2018 were collected. Kaplan-Meier method and parallel Log rank test were used for survival analysis. Cox regression model was used for univariate and multivariate analysis. A total of 90 CRC PC patients underwent CRS+ HIPEC, the median age was 53 years (rage: 13 to 81 years), and 51 cases were male, while other 39 were female. The median overall survival (mOS) was 21.9 months (95%CI: 15.7, 28.1). The 1-, 2-, 3-, and 5-year survival rates were 77.8%, 48.6%, 21.1%, and 5.5%, respectively. The incidence rate of serious adverse event (SAE) was 8.9% (8/90). The mortality rate of perioperative period was 2.2% (2/90). Univariate analysis showed the age (=0.040), primary tumor site (=0.020), preoperative carbohydrate antigen 125 (CA125) level (<0.001), peritoneal cancer index (PCI) (<0.001), completeness of cytoreduction (CC) (<0.001), ascites (=0.012) and postoperative adjuvant chemotherapy (<0.001) were significantly associated with the OS. Multivariate Cox-analysis identified preoperative CA125 level(=0.033), CC of 0 to 1 (=0.014), and adjuvant chemotherapy postoperative (=0.002) were independent prognostic factor for OS. CRS+ HIPEC can improve survival for CRC PC patients with acceptable morbidity and mortality. Stringent patient selection and complete CRS are two key factors for better survival.